Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

NCT07193394 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer ( HER2 Negative)
Unresectable Breast Cancer

Interventions

DRUG: Tucatinib (ONT-380)
DRUG: Trastuzumab (Herceptin)

Sponsor

Institut Curie

Collaborators

[object Object]
[object Object]
[object Object]